S. Jugl

发表

Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK

P. Emery, M. van Keep, S. Beard, 2018, PharmacoEconomics.

Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis

S. Jugl, K. Krüger, F. Meier, 2018, Rheumatology International.

Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis.

I. McInnes, H. Thom, E. Choy, 2018, Journal of comparative effectiveness research.

Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis.

V. Strand, P. Mease, I. McInnes, 2019, Journal of comparative effectiveness research.

Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2‐Year Results From a Multicenter, Randomized, Double‐Blind, Parallel‐Group, Placebo‐Controlled Phase III Study

L. Coates, B. Kirkham, P. Mease, 2018, Arthritis care & research.

Minimal Disease Activity among Active Psoriatic Arthritis Patients Treated with Secukinumab: 2-year Results from the FUTURE 2 Study

L. Coates, B. Kirkham, P. Mease, 2018 .

There is a risk of overtreatment when the Disease Activity Score in 28 joints is based solely on subjective parameters . A cross-sectional , exploratory , DANBIO study

P. Conaghan, L. Laasonen, A. Kavanaugh, 2016 .

Matching Adjusted Indirect Comparisons To Assess Comparative Effectiveness Of Therapies: Usage In Scientific Literature And Health Technology Appraisals

H. Thom, S. Jugl, S. Jawla, 2016 .

E68. IMPACT OF ALTERNATIVE DEFINITIONS OF TREATMENT RESPONSE ON LONG-TERM EFFICACY OF SECUKINUMAB IN TUMOUR NECROSIS FACTOR-ALPHA–NAÏVE PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS

Z. Tallóczy, N. Williams, S. Jugl, 2017 .

Epidemiology and Costs of Psoriatic Arthritis in Germany – A Retrospective Claims Data Analysis

M. Augustin, S. Jugl, F. Meier, 2016 .

Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study.

L. Coates, P. Mease, L. Gossec, 2020, Seminars in arthritis and rheumatism.

Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison.

P. Mease, H. Thom, E. Choy, 2019, European journal of rheumatology.

Unmet needs in psoriatic arthritis patients receiving immunomodulatory therapy: results from a large multinational real-world study

V. Strand, S. Blackburn, A. Deodhar, 2019, Clinical Rheumatology.

Secukinumab Provides Sustained Minimal Disease Activity (MDA) and Remission Related to Disease Activity Index for Psoriatic Arthritis (DAPSA): 2-Year Results from a Phase 3 Study

L. Coates, P. Mease, L. Gossec, 2017 .

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study

L. Coates, D. Gladman, V. Strand, 2018, Arthritis Research & Therapy.

Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study

V. Strand, B. Kirkham, P. Mease, 2018, Arthritis Research & Therapy.

Relationship of pain and fatigue with health-related quality of life and work in patients with psoriatic arthritis on TNFi: results of a multi-national real-world study

V. Strand, A. Deodhar, P. Conaghan, 2020, RMD Open.

Review of Patient Reported Outcome Measures used in Clinical and Cost-Effectiveness Studies to Measure Utilities in the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis.

S. Jugl, P. Gunda, S. Syeda, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study

V. Strand, A. Deodhar, P. Conaghan, 2020, BMC Rheumatology.

Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative

G. Colombo, S. Jugl, P. Gunda, 2018, ClinicoEconomics and outcomes research : CEOR.

Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective

R. Goeree, D. Gladman, C. Graham, 2018, Journal of medical economics.

Pain and Fatigue in Patients With Ankylosing Spondylitis Treated With Tumor Necrosis Factor Inhibitors

V. Strand, A. Deodhar, P. Conaghan, 2020, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison

P. Mease, I. McInnes, H. Thom, 2018, Rheumatology and Therapy.

Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study.

V. Strand, A. Deodhar, P. Conaghan, 2019, Clinical and experimental rheumatology.

THU0448 Secukinumab for The Treatment of Psoriatic Arthritis: Comparative Effectiveness Results versus Adalimumab Up To 48 Weeks Using A Matching-Adjusted Indirect Comparison

P. Mease, I. McInnes, H. Thom, 2016 .

Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison

V. Strand, H. Thom, W. Maksymowych, 2018, European journal of rheumatology.

Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective

R. Goeree, S. Jugl, P. Gunda, 2018, Journal of medical economics.

Comparative Effectiveness of Secukinumab and Adalimumab in Ankylosing Spondylitis as Assessed by Matching-Adjusted Indirect Comparison: An Analysis Based on All Pivotal Phase 3 Clinical Trial Data

J. Walsh, H. Thom, W. Maksymowych, 2017 .

AB0707 Comparative effectiveness of secukinumab and golimumab in ankylosing spondylitis assessed by matching-adjusted indirect comparison using pivotal phase 3 clinical trial data

H. Thom, E. Choy, S. Jugl, 2017 .

SAT0390 Secukinumab for The Treatment of Ankylosing Spondylitis: Comparative Effectiveness Results versus Currently Licensed Biologics from A Network Meta-Analysis

V. Strand, P. Mease, H. Thom, 2016 .

Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK

B. Kirkham, C. Graham, L. Miles, 2018, PharmacoEconomics.

THU0442 Reduction in Fatigue in Patients with Active Psoriatic Arthritis Are Sustained over 2 Years: Long-Term Results of Two Phase 3 Studies with Secukinumab

P. Conaghan, L. Gossec, M. Østergaard, 2016 .

Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis.

V. Strand, P. Mease, I. McInnes, 2019, Journal of comparative effectiveness research.

Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.

P. Mease, S. Jugl, S. Mpofu, 2018 .